300244.SZ
迪安诊断
SZSE · Healthcare · Q 卫生 · CN
CNY 19.82
−4.02%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 10.0B | 10.1B | 12.2B | 13.4B | 20.3B |
| Cost of Revenue | 7.1B | 7.2B | 8.8B | 9.2B | 12.7B |
| Gross Profit | 2.9B | 2.9B | 3.4B | 4.2B | 7.5B |
| Operating Expenses | |||||
| R&D Expense | 247.8M | 254.5M | 305.9M | 432.6M | 638.5M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 716.6M | 715.5M | 858.9M | 947.1M | 1.3B |
| Selling & Marketing Expense | 1.1B | 1.2B | 1.2B | 1.4B | 1.6B |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 2.3B | 2.3B | 2.6B | 3.0B | 3.9B |
| Cost and Expenses | 9.4B | 9.6B | 11.4B | 12.2B | 16.6B |
| Operating Income (EBIT) | 414.6M | 281.3M | (31.1M) | 842.2M | 2.8B |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 390.2M | 256.2M | (51.8M) | 798.3M | 2.5B |
| Income Tax Expense | 144.5M | 110.6M | 117.4M | 216.7M | 681.1M |
| Bottom Line | |||||
| Net Income | 129.4M | 44.1M | (357.3M) | 307.5M | 1.4B |
| Earnings from Cont. Ops | 245.6M | 145.6M | (169.2M) | 581.6M | 1.9B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 129.4M | 44.1M | (357.3M) | 307.5M | 1.4B |
| Per Share | |||||
| Basic EPS | CN¥0.21 | CN¥0.07 | (CN¥0.58) | CN¥0.49 | CN¥2.30 |
| Diluted EPS | CN¥0.21 | CN¥0.07 | (CN¥0.58) | CN¥0.49 | CN¥2.30 |
| Revenue Per Share | CN¥16.32 | CN¥16.52 | CN¥19.77 | CN¥21.45 | CN¥32.56 |
| Shares | |||||
| Basic Shares Outstanding | 611.3M | 611.0M | 617.1M | 625.2M | 623.0M |
| Diluted Shares Outstanding | 611.3M | 611.0M | 617.1M | 625.2M | 623.0M |
| Profitability Metrics | |||||
| EBITDA | — | 698.1M | 481.6M | 1.4B | 3.5B |
| D&A | — | 416.8M | 512.7M | 554.0M | 679.3M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026